London Stock Exchange welcomes HeiQ Plc to the Main Market

London Stock Exchange today welcomes HeiQ Plc (LSE: HEIQ) to trading on the Main Market. 

HeiQ is a global, profitable pioneer in the $24 billion textile chemicals market, directly serving the $10 billion antimicrobial textile market with its recent Swiss Technology Award-winning HeiQ Viroblock technology. Founded in 2005, HeiQ has grown into a high growth, cash generative company which employs more than 100 people around the world.

The Company has created some of the most effective, durable and high-performance textile technologies in the market today which cool, warm, dry, repel, purify and stop viruses. So far, HeiQ has developed over 200 technologies in partnership with over 300 major brands, including Burberry, GAP, New Balance, Patagonia, Speedo, The North Face and Zara.

The Company’s shares were admitted to the Standard Segment of the Official List of the Financial Conduct Authority at 8:00 am on Monday 7th December 2020 by way of a reverse take over into Auctus Growth Plc. The admission follows an oversubscribed placing and subscription, raising £60 million (before expenses) from institutional and other investors. 

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers – aiming for lab to consumer in a matter of months. 

HeiQ’s latest innovation - HeiQ Viroblock – is an award-winning antimicrobial technology which helps in the fight against enveloped viruses, including SARS-Cov-2 (the virus causing COVID-19). This technology is already being used by more than 150 major brands such as Burberry.

The Company’s aim is to deliver growth for its shareholders by driving increased sales of HeiQ’s core products and by entering additional lucrative markets through disruptive innovations:

  • Increasing market penetration of core innovations, including HeiQ Fresh AIR (developed for a leading Swedish home furnishing retailer); HeiQ Smart Temp (used by Japan’s biggest casual wear retailer and American clothing brand, Hanesbrands, Inc.) and HeiQ Clean Tech (winner of the Swiss Environmental Award in 2019).
     
  • Building on the significant momentum achieved by HeiQ Viroblock: developing HeiQ’s licensing and royalty business, which will see the brand name HeiQ Viroblock licensed together with the technology to third parties in return for royalty payments.
     
  • Developing new disruptive innovations: numerous projects in the R&D pipeline, including HeiQ GrapheneX for industrial filtration. The industrial filtration market was over $29 billion in 2020 - CAGR of 6.9% from the period of 2020 to 2025.

HeiQ Co-Founder & CEO Carlo Centonze said, “Today’s listing is a major milestone for HeiQ, and we are delighted to welcome our new investors aboard the ship. We have spent the past 15 years building HeiQ to become one of the leading textile materials innovators in the world, and the cash generative, high margin profile of our business demonstrates the success we have experienced. 

“The fundraise will enable HeiQ to build on the significant momentum achieved so far in 2020. There are many opportunities to capture more market share through increased sales of our core products to major brands. These have grown 17% in the first half of the year and, in parallel, we have entered lucrative new markets with additional high margin innovations.

“The antimicrobial market, which has grown into a mainstream request, also presents a compelling growth opportunity going forward. The launch of HeiQ Viroblock more than doubled HeiQ’s revenue in the first half of 2020. We look forward to innovating the antimicrobial field and regularly updating the market regarding new partnerships and contracts in the future. 

“We are in a robust financial position with a healthy balance sheet and revenue. We have been cash-generative for many years. The business has substantial IP, technology and regulatory permits which create strong barriers to entry. Management holds almost a quarter of the shares and are fully aligned with our original shareholders. Our brand equity has experienced strong growth which will likely lead to further requests by consumers. In summary, we believe the months and years ahead look bright for the enlarged group.”

HeiQ Plc has appointed Arlington Group Asset Management Limited as its financial adviser and joint broker, Cenkos Securities plc as joint broker and Newgate Communications as its UK public relations adviser. BDB Pitmans has acted as the UK legal adviser. 

Quick facts

Track
Market: Main Market
Instrument market cap (£m)
178.25
Listing/Admission to trading
07 Dec 2020
Looking for new and recent issues?

More recent

London International Shipping Week 2021

London International Shipping Week 2021 (LISW21) is seen throughout the world as the ‘must attend’ international maritime event of the year. London is the historic centre of global trade and world shipping and stands at the heart of international commerce. Its long-standing maritime institutions have been servicing the global shipping industry for centuries and that role co

Learn more
57.28
London Stock Exchange welcomes LungLife AI

London Stock Exchange welcomes LungLife AI, Inc. to trading on AIM. In July 2021 LungLife successfully raised gross proceeds of £17 million and the Company’s market capitalisation on admission was £45 million with a free float of 50.6%. 

LungLife AI’s mission is to make a significant impact in the early detection of lung cancer. The Company is a develop

Learn more
33.56
London Stock Exchange welcomes Likewise Group plc to AIM

Likewise is a UK distributor of both domestic and commercial floorcoverings and matting. It is challenging the established competitors in the industry by providing access to a wide choice of flooring from multiple manufacturers across the globe at competitive prices for its customers. The Directors believe they have an opportunity to build a

Learn more
144.88
London Stock Exchange welcomes BiVictriX Therapeutics plc

London Stock Exchange today welcomes BiVictriX Therapeutics plc (“BiVictriX”), a rapidly emerging drug discovery and development company that begins trading on AIM under the ticker symbol BVX, following a successful initial public offering.

BiVictriX has successfully raised gross proceeds of £

Learn more